Sr Sdet – Android

CRT 2025 Late Breaking Science features largest head-to-head randomized control TAVR trial to primarily enroll women using the two most widely used global TAVR devicesGALWAY, Ireland and WASHINGTON, March 9, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial, the largest international head-to-head comparative trial of transfemoral transcatheter aortic valve replacement (TAVR). In patients with aortic stenosis and a small aortic annulus, results showed comparable composite outcome of mortality, disabling stroke, and heart failure hospitalization, and continued superior valve performance as measured by bioprosthetic valve dysfunction (BVD) at two years for Evolut™ TAVR compared to SAPIEN™. The late-breaking science was presented at the Cardiovascular Research Technologies (CRT) 2025 conference in Washington, D.C."Valve performance is critical for all patients, but the impact of poor valve performance is magnified in patients with a small aortic annulus, who are at risk of receiving a valve that is not adequate for their cardiac requirements," said Howard C. Herrmann, M.D., Perelman School of Medicine at the University of Pennsylvania, and lead investigator of the trial. "The two-year results highlight the continued superior performance of the Evolut TAVR valve in these patients. While we would not yet expect to see a significant difference in the composite clinical outcomes at this early stage, valve performance provides important data that operators can use to inform and personalize treatment decisions to enhance patient outcomes."The SMART two-year data demonstrated that Evolut TAVR continues to show significantly less BVD, which can be a predictor of adverse outcomes1, compared to SAPIEN TAVR

GALWAY, Ireland, March 6, 2025 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE: MDT) on Thursday, March 6, 2025, approved the company's cash dividend for the fourth quarter of fiscal year 2025 of $0.70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the SP 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividend is payable on April 11, 2025, to shareholders of record at the close of business on March 28, 2025. About MedtronicBold thinking. Bolder actions

CLEVELAND, Ohio, March 4, 2025 /PRNewswire/ -- JumpStart Ventures has achieved the successful first close of NEXT Fund III, raising nearly $25 million toward its $50 million target. NEXT Fund III is supported by the State Small Business Credit Initiative (SSBCI) Ohio, institutional and private investors and reinforces JumpStart Ventures' commitment to providing tech founders with the capital they need to scale their startups.NEXT Fund III will invest in Seed and Series A startups and build upon JumpStart Ventures' two decades of experience supporting high-growth startups with risk capital while generating top returns for their investment partners.NEXT Fund III is JumpStart Ventures' third fund under its NEXT model and its eighth venture capital fund overall. With this first close, JumpStart Ventures is positioned to continue its momentum of funding high-growth startups."This close represents a significant step forward in supporting our region's most ambitious founders," said Hardik Desai, Managing Partner of JumpStart Ventures. "With the backing of our committed partners, we are focused on providing the capital and resources needed to help founders scale their businesses and bring groundbreaking technologies to market."JumpStart Ventures' portfolio has brought much excitement to the region's venture capital ecosystem in recent years, as demonstrated by the growth of several venture-backed startups like Abre, Centerline Biomedical, OnStation, Cleveland Diagnostics, Orthobrain, Axuall and Onshift. 30+ portfolio companies like CoverMyMeds, Able Software, Wireless Environment, CardioInsight, and Vizzle have been acquired generating significant returns for the investors.JumpStart Ventures manages four unique investment funds to drive startup growth, pairing stage-appropriate capital with deep connections and partnerships. As one of Ohio's most active early-stage investors, the organization's investment activities have generated top quartile investment returns via nationally recognized exits and fundraises